KROS FY 2024 Earnings — Keros Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

KROSKeros Therapeutics, Inc.

$414M

FY 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$4M+2251.0% YoY

Gross Profit

$4M100.0% margin

Operating Income

-$211M-5939.0% margin

Net Income

-$187M-5277.5% margin

EPS (Diluted)

$-5.00

Cash Flow

Operating Cash Flow

-$161M

Free Cash Flow

-$163M

Stock-Based Comp.

$35M

Balance Sheet

Total Assets

$616M

Total Liabilities

$44M

Stockholders' Equity

$572M

Cash & Equivalents

$560M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4M	$151,000	+2251.0%
Gross Profit	$4M	$151,000	+2251.0%
Operating Income	-$211M	-$170M	-24.1%
Net Income	-$187M	-$153M	-22.5%